73035-16-2

Basic information

• Product Name: 3-ACETYLBENZENESULFONYL CHLORIDE
• Synonyms: AKOS BB-9466;3-ACETYLBENZENESULFONYL CHLORIDE;Benzenesulfonyl chloride, 3-acetyl- (9CI);3-Acetylbenzenesulfonyl chloride, GC 97%
• CAS NO: 73035-16-2
• Molecular Formula: C₈H₇ClO₃S
• Molecular Weight: 218.66
• Product Categories: SULFONYLHALIDE
• Mol File: 73035-16-2.mol
• Article Data: 4

Chemical Properties

• Melting Point: 43-45°C
• Boiling Point: 347 °C at 760 mmHg
• Flash Point: 163.7 °C
• Appearance: /
• Density: 1.387g/cm³
• Vapor Pressure: 5.54E-05mmHg at 25°C
• Refractive Index: 1.544
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Sensitive: Moisture Sensitive
• CAS DataBase Reference: 3-ACETYLBENZENESULFONYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-ACETYLBENZENESULFONYL CHLORIDE(73035-16-2)
• EPA Substance Registry System: 3-ACETYLBENZENESULFONYL CHLORIDE(73035-16-2)

Safety Data

• HazardClass: 8
• Hazardous Substances Data: 73035-16-2(Hazardous Substances Data)

Usage

Uses

Classical acetamidomalonate addition/decarboxylative hydrolysis as the key step for the generation of the amino acidic moiety starting from 4-ethylsulfonyl-α-bromoacetophenone prepared in two steps from commercially available 4-acetyl-benzenesulfonyl chloride. This then treated with sodium sulfite in basic aqueous conditions yielded the sodium sulfinate.

InChI:InChI=1/C8H7ClO3S/c1-6(10)7-3-2-4-8(5-7)13(9,11)12/h2-5H,1H3

Upstream product

• 99-03-6 1-(3-aminophenyl)ethanone 

Downstream Products

• 881676-84-2 1-[(3-acetylphenyl)sulfonyl]-5-phenyl-1H-pyrrole-3-carbaldehyde 
• 1186421-63-5 N,N-dimethyl-3-(3-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)-2-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-7-yl)benzenesulfonamide 
• 1186421-69-1 3-[3-(7-methoxy-1H-indazol-4-yl)-2-pyridin-4-ylpyrazolo[1,5-a]pyrimidin-7-yl]-N,N-dimethylbenzenesulfonamide 
• 1186421-60-2 3-(3-(1H-indol-4-yl)-2-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-7-yl)-N,N-dimethylbenzenesulfonamide 
• 1186421-66-8 3-(3-(1H-indol-6-yl)-2-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-7-yl)-n,n-dimethylbenzenesulfonamide 
• 1186421-53-3 3-(3-(1H-indazol-4-yl)-2-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-7-yl)-n,n-dimethylbenzenesulfonamide 
• 1186421-45-3 3-(3-(3-hydroxyphenyl)-2-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-7-yl)-N-methylbenzenesulfonamide 
• 1186421-43-1 3-[3-(3-hydroxyphenyl)-2-pyridin-4-ylpyrazolo[1,5-a]pyrimidin-7-yl]-N,N-dimethylbenzenesulfonamide 
• 1186422-01-4 3-(3-iodo-2-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-7-yl)-N,N-dimethylbenzenesulfonamide 
• 1186421-98-6 N,N-dimethyl-3-(2-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-7-yl)benzenesulfonamide 
• 1310456-95-1 3-(3-(dimethylamino)acryloyl)-N,N-dimethylbenzenesulfonamide 
• 1441-99-2 1-[3-(methylsulfanyl)phenyl]ethan-1-one 
• 89102-48-7 2-bromo-1-(3-mercaptophenyl)ethanone 

Relevant articles and documents

4-PHENYL-N-(PHENYL)THIAZOL-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS FOR THE TREATMENT OF E.G. ANGIOGENESIS IMPLICATED OR INFLAMMATORY DISORDERS

4-phenyl-N-(phenyl)thiazol-2-amine and 4-(pyridin-3-yl)-N-( phenyl) thiazol-2-amine derivatives and the corresponding thiadiazole, thiophene, oxazole, oxadiazole, imidazole and triazole derivatives and related compounds as aryl hydrocarbon receptor (AHR) agonists for the treatment of angiogenesis implicated disorders, such as e.g. retinopathy, psoriasis, rheumatoid arthritis, obesity and cancer, or inflammatory disorders.

Dihydrothiazolone compounds containing sulfamide and pharmaceutical compositions and use thereof

The invention provides dihydrothiazolone compounds containing sulfamide, represented by a formula (I), pharmaceutical compositions and use thereof. The compounds can be combined with proteins with bromodomain structural domains so as to adjust a downstream signal channel and exert a special function, and can be used for treating many diseases associated with bromodomain structural domains. The compounds can interfere combination of Brd4 with the bromodomain structural domain and an acetylized histone so as to down-regulate transcription of a cancer gene c-myc and associated target genes thereof, so that the compounds can become effective therapeutic drugs for treating tumors.